Featured News
The GW VRU Director, Dr. David Diemert, co-authored an article assessing the value of public health, economic, and societal value of developing a vaccine to prevent and reduce the transmission of Schistosomiasis. Endemic in 78 countries, it is estimated that approximately 236 million people were…
VRU Director, Dr. David Diemert, attends the annual Joint Coordinating Board meeting of TDR (Special Programme for Research and Training in Tropical Diseases) of the WHO in Geneva, Switzerland
The GW VRU Director, Dr. David Diemert, weighs in on two candidate vaccine viruses for H5N1 bird flu that could be used to make vaccines in an outbreak.
Study Highlights Need for Defined Markers of Mpox Immunity to Inform Public Health Use
George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.
Read more information about how The George Washington Vaccine Research Unit is looking for adolescents between the ages of 12 and 17 to participate in a Mpox vaccine trial. The need for adolescents is vital for researchers to get an approved vaccine for adolescents to prevent another outbreak.
Here is more information about the NIH trials and what Dr. Diemert and other infectious disease experts have to say about the progress in the monkeypox vaccine.
Check out this interview with our very own Dr. Diemert, the director of the GW Vaccine Research Unit on WTOP to learn more about our current monkeypox trial.
NIH Trial is Evaluating Intradermal Delivery to Expand the Vaccine Supply.